$ZOM
Zomedica Corp.

2023 Q4 Form 10-Q Financial Statement

#000155837023018830 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $7.337M $6.347M $4.776M
YoY Change 19.17% 32.89% 21113.47%
Cost Of Revenue $2.264M $1.985M $1.215M
YoY Change 21.52% 63.37% 6688.09%
Gross Profit $5.073M $4.362M $3.561M
YoY Change 18.14% 22.49% 77061.43%
Gross Profit Margin 69.14% 68.73% 74.56%
Selling, General & Admin $13.36M $9.443M $9.022M
YoY Change 54.43% 4.67% 47.31%
% of Gross Profit 263.41% 216.48% 253.36%
Research & Development $3.099M $867.0K $1.131M
YoY Change 298.84% -23.34% 292.09%
% of Gross Profit 61.09% 19.88% 31.76%
Depreciation & Amortization $1.870M $1.596M $109.0K
YoY Change 51.79% 1364.22% 80.33%
% of Gross Profit 36.86% 36.59% 3.06%
Operating Expenses $16.46M $10.31M $10.15M
YoY Change 74.57% 1.55% 58.32%
Operating Profit -$11.39M -$5.948M -$6.592M
YoY Change 121.75% -9.77% 2.87%
Interest Expense $1.231M $64.00K $945.0K
YoY Change -3.45% -93.23%
% of Operating Profit
Other Income/Expense, Net -$115.0K $2.195M -$5.000K
YoY Change -11600.0% -44000.0% -933.33%
Pretax Income -$21.95M -$2.411M -$5.652M
YoY Change 468.87% -57.34% -10.93%
Income Tax $459.0K -$1.920M -$657.0K
% Of Pretax Income
Net Earnings -$22.41M -$491.0K -$4.995M
YoY Change 697.65% -90.17% -21.29%
Net Earnings / Revenue -305.38% -7.74% -104.59%
Basic Earnings Per Share $0.00 -$0.01
Diluted Earnings Per Share -$0.02 $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 979.9M 979.9M 979.9M
Diluted Shares Outstanding 979.9M 979.9M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.50M $106.2M $119.3M
YoY Change -21.37% -10.97% -56.05%
Cash & Equivalents $12.95M $21.78M $45.10M
Short-Term Investments $77.55M $84.42M $74.20M
Other Short-Term Assets $2.064M $3.018M $3.611M
YoY Change -45.67% -16.42% 121.01%
Inventory $5.123M $3.737M $2.400M
Prepaid Expenses
Receivables $1.197M $1.348M $719.0K
Other Receivables $1.001M $1.084M $1.078M
Total Short-Term Assets $99.88M $115.4M $127.1M
YoY Change -19.12% -9.21% -53.74%
LONG-TERM ASSETS
Property, Plant & Equipment $10.35M $8.259M $6.727M
YoY Change 51.96% 22.77% 852.47%
Goodwill $61.58M $73.77M $64.23M
YoY Change -3.75% 14.86%
Intangibles $55.36M $56.93M $42.78M
YoY Change 32.45% 33.08% 8925.54%
Long-Term Investments $10.01M $11.79M $39.20M
YoY Change -75.42% -69.93%
Other Assets $822.0K $852.0K $265.0K
YoY Change 210.19% 221.51% 57.72%
Total Long-Term Assets $153.3M $159.7M $155.2M
YoY Change -1.79% 2.88% 5506.71%
TOTAL ASSETS
Total Short-Term Assets $99.88M $115.4M $127.1M
Total Long-Term Assets $153.3M $159.7M $155.2M
Total Assets $253.2M $275.1M $282.3M
YoY Change -9.45% -2.57% 1.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.668M $5.598M $6.244M
YoY Change 14.48% -10.35% 39.85%
Accrued Expenses $981.0K $114.0K $41.00K
YoY Change 424.6% 178.05%
Deferred Revenue $276.0K $257.0K $205.0K
YoY Change 33.33% 25.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $679.0K $578.0K
YoY Change 17.47%
Total Short-Term Liabilities $9.032M $6.740M $7.126M
YoY Change 15.63% -5.42% 46.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.073M $1.058M
YoY Change -100.0% 1.42% -1.09%
Other Long-Term Liabilities $944.0K $1.433M $2.872M
YoY Change -49.87% -50.1% 168.49%
Total Long-Term Liabilities $944.0K $1.433M $2.872M
YoY Change -49.87% -50.1% 181.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.032M $6.740M $7.126M
Total Long-Term Liabilities $944.0K $1.433M $2.872M
Total Liabilities $13.18M $14.17M $13.52M
YoY Change 7.87% 4.81% 127.51%
SHAREHOLDERS EQUITY
Retained Earnings -$170.9M -$148.5M -$133.6M
YoY Change 25.31% 11.17% 15.07%
Common Stock $410.9M $409.8M $403.2M
YoY Change 1.55% 1.64% 4.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $240.0M $260.9M $268.8M
YoY Change
Total Liabilities & Shareholders Equity $253.2M $275.1M $282.3M
YoY Change -9.45% -2.57% 1.73%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$22.41M -$491.0K -$4.995M
YoY Change 697.65% -90.17% -21.29%
Depreciation, Depletion And Amortization $1.870M $1.596M $109.0K
YoY Change 51.79% 1364.22% 80.33%
Cash From Operating Activities -$5.015M -$3.027M -$2.770M
YoY Change 110.45% 9.28% -44.58%
INVESTING ACTIVITIES
Capital Expenditures $2.065M $9.215M -$1.849M
YoY Change 161.39% -598.38% 819.12%
Acquisitions
YoY Change
Other Investing Activities -$1.764M $6.092M -$137.0M
YoY Change -87.89% -104.45% -91358100.0%
Cash From Investing Activities -$3.829M -$3.123M -$138.9M
YoY Change -75.06% -97.75% 68990.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 8.000K
YoY Change -100.0% -98.0%
NET CHANGE
Cash From Operating Activities -5.015M -3.027M -2.770M
Cash From Investing Activities -3.829M -3.123M -138.9M
Cash From Financing Activities 0.000 8.000K
Net Change In Cash -8.844M -6.150M -141.6M
YoY Change -50.13% -95.66% 2851.76%
FREE CASH FLOW
Cash From Operating Activities -$5.015M -$3.027M -$2.770M
Capital Expenditures $2.065M $9.215M -$1.849M
Free Cash Flow -$7.080M -$12.24M -$921.0K
YoY Change 123.13% 1229.21% -80.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001684144
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
979949668
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
979949668
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38298
dei Entity Registrant Name
EntityRegistrantName
Zomedica Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Phoenix Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 125
dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
dei City Area Code
CityAreaCode
734
dei Local Phone Number
LocalPhoneNumber
369-2555
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Shares
dei Trading Symbol
TradingSymbol
ZOM
dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
979949668
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21783000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27399000
CY2023Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
84424000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
87693000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1348000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
596000
CY2023Q3 us-gaap Inventory Net
InventoryNet
3737000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2746000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3018000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3799000
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1084000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1268000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
115394000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
123501000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
98000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
188000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8259000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6809000
CY2023Q3 zom Asset Construction In Progress Non Current
AssetConstructionInProgressNonCurrent
6279000
CY2022Q4 zom Asset Construction In Progress Non Current
AssetConstructionInProgressNonCurrent
692000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1681000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665000
CY2023Q3 us-gaap Goodwill
Goodwill
73774000
CY2022Q4 us-gaap Goodwill
Goodwill
63979000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
56928000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41799000
CY2023Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
11787000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
40712000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
852000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
265000
CY2023Q3 us-gaap Assets
Assets
275052000
CY2022Q4 us-gaap Assets
Assets
279610000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5598000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6698000
CY2023Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
114000
CY2022Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
187000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
679000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
257000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
207000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
92000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6740000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7811000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1073000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1097000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
998000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1245000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
270000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
182000
CY2023Q3 zom Supplier Finance Program Obligation Noncurrent
SupplierFinanceProgramObligationNoncurrent
3654000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1433000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1884000
CY2023Q3 us-gaap Liabilities
Liabilities
14168000
CY2022Q4 us-gaap Liabilities
Liabilities
12219000
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
979949668
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
979949668
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
380973000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
380973000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
28824000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
23666000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148526000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136403000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-387000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-845000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
260884000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267391000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275052000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279610000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6347000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4776000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17849000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12773000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1985000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1265000
us-gaap Cost Of Revenue
CostOfRevenue
5604000
us-gaap Cost Of Revenue
CostOfRevenue
3516000
CY2023Q3 us-gaap Gross Profit
GrossProfit
4362000
CY2022Q3 us-gaap Gross Profit
GrossProfit
3511000
us-gaap Gross Profit
GrossProfit
12245000
us-gaap Gross Profit
GrossProfit
9257000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6115000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5153000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19977000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17691000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
867000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1215000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2645000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1885000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3328000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3735000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9826000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6468000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5948000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6592000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20203000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16787000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1437000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1012000
us-gaap Investment Income Net
InvestmentIncomeNet
4309000
us-gaap Investment Income Net
InvestmentIncomeNet
1396000
CY2023Q3 us-gaap Interest Expense
InterestExpense
64000
us-gaap Interest Expense
InterestExpense
175000
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
14000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
15000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2195000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2195000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-45000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-67000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-54000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-123000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2411000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5652000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13913000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15523000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1920000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-657000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1790000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1317000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-491000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4995000
us-gaap Net Income Loss
NetIncomeLoss
-12123000
us-gaap Net Income Loss
NetIncomeLoss
-14206000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
244000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-803000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
520000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-803000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-19000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-32000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-62000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-21000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-266000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5830000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11665000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15030000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.005
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.012
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.014
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267391000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5158000
us-gaap Net Income Loss
NetIncomeLoss
-12123000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
458000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
260884000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
259482000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1668000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-491000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
225000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
260884000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
270886000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6452000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6465000
zom Stock Issued Due To Exercise Of Warrants Amount
StockIssuedDueToExerciseOfWarrantsAmount
8000
us-gaap Net Income Loss
NetIncomeLoss
-14206000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-824000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
268781000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
266218000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1920000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6465000
CY2022Q3 zom Stock Issued Due To Exercise Of Warrants Amount
StockIssuedDueToExerciseOfWarrantsAmount
8000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4995000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-835000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
268781000
us-gaap Net Income Loss
NetIncomeLoss
-12123000
us-gaap Net Income Loss
NetIncomeLoss
-14206000
us-gaap Depreciation
Depreciation
538000
us-gaap Depreciation
Depreciation
270000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3890000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2540000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
2174000
us-gaap Share Based Compensation
ShareBasedCompensation
5158000
us-gaap Share Based Compensation
ShareBasedCompensation
6452000
zom Non Cash Portion Of Rent Benefit Expense
NonCashPortionOfRentBenefitExpense
2000
zom Non Cash Portion Of Rent Benefit Expense
NonCashPortionOfRentBenefitExpense
-9000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1716000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
400000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1350000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3637000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-616000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1330000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
737000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
442000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-193000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-69000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1085000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3020000
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-73000
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-199000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-1960000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-1319000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
14000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-204000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
137000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
81000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-271000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
8000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10960000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9287000
zom Proceeds From Repayments Of Available For Sale Securities
ProceedsFromRepaymentsOfAvailableForSaleSecurities
33240000
zom Proceeds From Repayments Of Available For Sale Securities
ProceedsFromRepaymentsOfAvailableForSaleSecurities
-113225000
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1750000
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
381000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
583000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4120000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
143000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
8923000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
1274000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
12660000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
24304000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5406000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-140529000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5554000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-149808000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-62000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-49000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27399000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194952000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21783000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45095000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
520000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-803000
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
2839000
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
2419000
zom Transfer Of Inventory Into Property And Equipment
TransferOfInventoryIntoPropertyAndEquipment
582000
zom Transfer Of Inventory Into Property And Equipment
TransferOfInventoryIntoPropertyAndEquipment
4291000
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
2550000
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
406000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Estimates and Assumptions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Comparative Figures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">A portion of depreciation expense for the three and nine months ended September 30, 2023 has been stated as part of cost of revenue for $122 and $315 respectively. The consolidated statements of income and comprehensive loss for the three and nine months ended September 30, 2022 have been adjusted for $50 and $101 respectively for depreciation that was included in selling, general, and administrative expense. This amount has been reclassified to cost of revenue to conform to the current year presentation. The change in presentation had no effect on the reported results of operations and does not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">To better align with the way in which we measure and track our business, we have changed the categorization of products within our segmentation of revenue. A portion of the products in our Therapeutic Device segment were previously designated as instruments and trodes in our form 10Q for the period ending September 30, 2022. These products have since been renamed to be capital and consumables to better align with our other platforms and to provide a more consistent baseline for comparison of the product lines within. Capital refers to the devices we sell within our PulseVet<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, Revo Squared<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, TRUVIEW™ and VetGuardian<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> product lines. Consumables continues to include our TRUFORMA<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> cartridges as it did last year and now includes our PulseVet trodes as well as our Assisi<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> products. There have been no changes to the overall sales numbers for our Diagnostics and Therapeutic Device segments, only the product names making up the total. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">To provide further clarity on the way in which we present our operating expenses, we have broken up our SG&amp;A spend into distinct and separate General and Administrative and Selling and Marketing line items on the consolidated statements of income and comprehensive loss for the three and nine months ended September 30, 2023. The consolidated statements of income and comprehensive loss for the three and nine months ended September 30, 2022 have been adjusted to conform to the current year presentation of operating expenses. The change in presentation had no effect on the reported results of operations and does not affect previously reported cash flows from operating activities in the consolidated statements of cash flows. </p>
CY2023Q3 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
122000
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
315000
zom Accounts Receivables Payment Term
AccountsReceivablesPaymentTerm
P30D
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
79000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6347000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4776000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17849000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12773000
CY2023Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
101860000
CY2023Q3 zom Investment Securities Accumulated Accretion Or Amortization
InvestmentSecuritiesAccumulatedAccretionOrAmortization
928000
CY2023Q3 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
541000
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
102247000
CY2022Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
147797000
CY2022Q4 zom Investment Securities Accumulated Accretion Or Amortization
InvestmentSecuritiesAccumulatedAccretionOrAmortization
847000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
1061000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
147583000
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
693000
CY2023Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
101860000
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
102247000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8569000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4680000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
56928000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41799000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4000000
CY2023Q1 zom Supplier Finance Program Obligation Noncurrent
SupplierFinanceProgramObligationNoncurrent
4000000
CY2023Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2701000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1685000
CY2023Q3 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
496000
CY2022Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
182000
CY2023Q3 zom Inventory Purchase
InventoryPurchase
568000
CY2022Q4 zom Inventory Purchase
InventoryPurchase
919000
CY2023Q3 us-gaap Inventory Gross
InventoryGross
3765000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2786000
CY2023Q3 us-gaap Inventory Adjustments
InventoryAdjustments
28000
CY2022Q4 us-gaap Inventory Adjustments
InventoryAdjustments
40000
CY2023Q3 us-gaap Inventory Net
InventoryNet
3737000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2746000
CY2023Q3 us-gaap Deposit Assets
DepositAssets
1888000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
1886000
CY2023Q3 us-gaap Prepaid Advertising
PrepaidAdvertising
193000
CY2022Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
114000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
520000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
614000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
753000
CY2023Q3 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
515000
CY2022Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
620000
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3116000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3987000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10069000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8086000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1810000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1277000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8259000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6809000
us-gaap Depreciation
Depreciation
538000
us-gaap Depreciation
Depreciation
270000
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
65497000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
46479000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1578000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6259000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6095000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5632000
CY2023Q3 zom Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter
36801000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
56365000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3890000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2540000
CY2023Q3 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
3252000
CY2022Q4 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
2759000
CY2023Q3 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
372000
CY2022Q4 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
262000
CY2023Q3 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
2880000
CY2022Q4 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
2497000
CY2023Q3 zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1349000
CY2022Q4 zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
946000
CY2023Q3 zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
150000
CY2022Q4 zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
114000
CY2023Q3 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
1199000
CY2022Q4 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
832000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1681000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665000
zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
2921000
CY2022 zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
2520000
us-gaap Operating Lease Payments
OperatingLeasePayments
1319000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
896000
zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
150000
CY2022 zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
114000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1752000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1738000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
679000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1073000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1097000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1752000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1738000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
196000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
755000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
316000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
279000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
248000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
180000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1974000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
222000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1752000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.059
us-gaap Operating Lease Expense
OperatingLeaseExpense
629000
us-gaap Operating Lease Expense
OperatingLeaseExpense
598000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1110000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9275000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1110000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9275000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7075000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
28075000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7075000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
28075000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
84112443
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3602
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9275000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.2327
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2507500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.3292
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1002500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.9126
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
89877443
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3397
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
31648974
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.3476
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
89877443
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
31648974
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
58228469
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.96
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0047
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y6M10D
CY2020Q4 us-gaap Share Price
SharePrice
0.21
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.22
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.17
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0109
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
CY2021Q4 us-gaap Share Price
SharePrice
0.65
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.66
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.12
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0311
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2022Q4 us-gaap Share Price
SharePrice
0.26
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0375
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q3 us-gaap Share Price
SharePrice
0.23
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.23
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1668000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5158000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1920000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6452000
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32561418
zom Sub Total Warrant Exercised Shares
SubTotalWarrantExercisedShares
360129250
zom Sub Total Warrant Amount
SubTotalWarrantAmount
56933000
zom Class Of Warrants Expired
ClassOfWarrantsExpired
351000
zom Warrants Expired Amount
WarrantsExpiredAmount
55000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.014
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17849000
us-gaap Cost Of Revenue
CostOfRevenue
5604000
us-gaap Gross Profit
GrossProfit
12245000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-491000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4995000
us-gaap Net Income Loss
NetIncomeLoss
-12123000
us-gaap Net Income Loss
NetIncomeLoss
-14206000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-491000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4995000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12123000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14206000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.005
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.012

Files In Submission

Name View Source Status
zom-20230930_cal.xml Edgar Link unprocessable
0001558370-23-018830-index-headers.html Edgar Link pending
0001558370-23-018830-index.html Edgar Link pending
0001558370-23-018830.txt Edgar Link pending
0001558370-23-018830-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20230930.xsd Edgar Link pending
zom-20230930x10q.htm Edgar Link pending
zom-20230930xex21d1.htm Edgar Link pending
zom-20230930xex31d1.htm Edgar Link pending
zom-20230930xex31d2.htm Edgar Link pending
zom-20230930xex32d1.htm Edgar Link pending
zom-20230930_def.xml Edgar Link unprocessable
zom-20230930_lab.xml Edgar Link unprocessable
zom-20230930_pre.xml Edgar Link unprocessable
zom-20230930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable